• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Delcath's cancer-treating system lands U.S., Australian regulatory wins

November 5, 2012 By drugdelivery

Delcath logo

Medical device company Delcath Systems (NSDQ:DCTH) is on a roll, notching a couple new regulatory milestones this month for its organ-isolating ChemoSat chemotherapy treatment systems.

Delcath today announced that its 2nd-generation ChemoSat won regulatory approval from Australia’s Therapeutic Goods Administration and that the FDA granted the company a June 13, 2013, date for standard review of its recently accepted New Drug Application.

The New York-based company has had a string of recent wins, having in recent weeks landed expanded CE Mark approval in the European Union for ChemoSat, shortly after successfully filing its 2nd NDA with the FDA.

Delcath’s ChemoSat uses a system of tubes to localize the delivery of toxic chemotherapy agents by isolating the targeted organ from the rest of the body’s bloodstream.

The Australian approval grants the company approval to sell the 2nd-generation of the device in that country.

"Australian regulatory approval of our Generation Two ChemoSat system with melphalan for injection represents our 1st approval of the new system in the Pacific Rim," Delcath president & CEO Eamonn Hobbs said in prepared remarks. "This approval is another significant milestone for Delcath, since it enhances our opportunity to address a potential market of $50-70 million as we seek an exclusive distributor in this region."

Delcath must seek U.S. approval for the system under the pharmaceutical review pathway because of the melphalan hydrochloride the ChemoSat system uses to destroy cancerous tissue.

The recent luck is a welcome turnaround, as Delcath has had a rough go with the ChemoSat system in the last couple years, with inconclusive trial results and a 5-million-share stock offering that didn’t win much favor from The Street.

The troubles began when the FDA refused the company’s 1st new drug application over concerns that the information provided was insufficient for review. ChemoSat is regulated as a medical device in Europe, where it won CE Mark approval in April 2011, but as far as the FDA is concerned it is regulated as drug-device combination that also requires new drug labeling.

Filed Under: Drug-Device Combinations Tagged With: Delcath Systems Inc.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS